SAG
DNTH icon

SageView Advisory Group’s Dianthus Therapeutics DNTH Stock Holding History

SageView Advisory Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed -$289 – 1075
2025
Q4 		$289 Buy
+7
New +$271 ﹤0.01% 2488

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SageView Advisory Group's DNTH Position: Q1 2026 in Review

SageView Advisory Group sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 7 shares — an estimated $289 sold.

SageView Advisory Group first reported a position in DNTH in Q4 2025 and held it in 1 quarter. The position peaked at $289 in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • SageView Advisory Group reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 7 Dianthus Therapeutics shares in Q1 2026, an estimated $289.
  • SageView Advisory Group first reported a position in Dianthus Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Dianthus Therapeutics position peaked at $289 in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.